Business
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
JERSEY CITY, N.J., February 12, 2026--Organon announces Q4 2025 and Full Year 2025 earnings results, ending December 31, 2025.
About this update from Organon & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2100,"height":315,"url":"https://media.zenfs.com/en/business-wire.com/1cc353edfdda1c23f47a234d71c6341b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/M_y1oBISp16JWqyrL7cl9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE0NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1cc353edfdda1c23f47a234d71c6341b","width":960,"height":144},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/q3R44dVbT1GdPbSPdX_thg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zNjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/1cc353edfdda1c23f47a234d71c6341b","width":1200,"height":180}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Full year 2025 revenue of $6.2 billion, down 3% on both an as-reported basis and at constant currency","length":101,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Full year 2025 diluted earnings per share of $0.72 and non-GAAP Adjusted diluted earnings per share of $3.66","length":108,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Full year 2025 Adjusted EBITDA of $1.91 billion inclusive of $6 million of IPR&D, representing a 30.7% Adjusted EBITDA margin","length":129,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The company expects to deliver approximately $6.2 billion of revenue and approximately $1.9 billion of Adjusted EBITDA for the full year 2026, both measures in-line with full year 2025 performance.","length":197,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":535,"olType":false},{"type":"text","content":"JERSEY CITY, N.J., February 12, 2026--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2025.","length":164,"tagName":"p"},{"type":"text","content":""In 2025 we took action that demonstrated our commitment to improving the balance sheet and to building more financial flexibility," said Joe Morrissey, Organon’s interim Chief Executive Officer. "In 2026 our primary objective is to maintain operational performance that aligns with last year. At the same time, we remain committed to disciplined expense management and capital deployment to achieve progress on our deleveraging efforts."","lengt...